Եվրոպական Միություն - դանիերեն - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - bryst neoplasmer - endokrine terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i præ - eller perimenopausal kvinder, kombinationen behandling med palbociclib bør kombineres med en luteiniserende hormon releasing hormon (lhrh) agonist.

Դանիա - դանիերեն - SEGES Landbrug & Fødevarer

basf a/s - dimethomorph, mancozeb - vanddispergerbart granulat - 75 g/kg dimethomorph ; 667 g/kg mancozeb

Դանիա - դանիերեն - Adama

adama - propaquizafop 100 g/l - herbicider

Եվրոպական Միություն - դանիերեն - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopisk - andre dermatologiske præparater - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Եվրոպական Միություն - դանիերեն - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Դանիա - դանիերեն - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm healthcare a/s - warfarinnatrium - tabletter - 2,5 mg

Դանիա - դանիերեն - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - warfarinnatrium - tabletter - 2,5 mg

Դանիա - դանիերեն - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - warfarinnatrium - tabletter - 2,5 mg

Դանիա - դանիերեն - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - warfarinnatrium - tabletter - 2,5 mg

Եվրոպական Միություն - դանիերեն - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystisk fibrose - andet respirationssystem produkter - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.